AAO: Alimera highlights NEW DAY Study for sustained-release intravitreal implant

Video
Conference|AAO

Rick Eiswirth, president and CEO of Alimera Sciences, provides an update on the company’s clinical trial that aims to evaluate its fluocinolone acetonide intravitreal implant 0.19 mg (Iluvien) as a baseline therapy for diabetic macular edema.


Rick Eiswirth, president and CEO of Alimera Sciences, provides an update on the company’s clinical trial that aims to evaluate its fluocinolone acetonide intravitreal implant 0.19 mg (Iluvien) as a baseline therapy for diabetic macular edema.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Recent Videos
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
Mario Romano, MD, PhD, stresses the importance of thermodynamic control in vitrectomy during the 2025 European Society of Retina Specialists meeting. Photo shows Prof Romano on-camera at the Ophthalmology Times Europe and Modern Retina booth during EURETINA.
Related Content
A lightbulb hovering in an open box, in a room full of closed boxes. Image concept for "thinking outside the box," and revisiting or amending perspectives to treatment of retinal disease. Image credit: ©masterzphotofo – stock.adobe.com

Broader perspective for the treatment approach on retinal neovascular diseases

Fanka Gilevska, MD, PhD
October 8th 2025
Article
PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

October 8th 2025
Podcast
An elderly woman with glasses sits on a grassy hillside, near a tranquil blue lake. Concept image for geographic atrophy and vision-related quality of life measures. ©CameraCraft – stock.adobe.com

Intravitreal complement inhibitor treatment for GA viewed favorably by patients

Lynda Charters
October 8th 2025
Article
PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

October 8th 2025
Podcast
Stela Vujosevic, Md, PhD, FEBO, speaks about the need for a new staging system in diabetic eye disease during the 2025 European Society of Retina Specialists (EURETINA) meeting in Paris, France.

EURETINA 2025: Diabetic eye disease needs a new staging system

Stela Vujosevic, Md, PhD, FEBO;Hattie Hayes;Sydney M Crago
October 8th 2025
Article
A hand writes a check mark in a box. It is superimposed over an image of samples in a laboratory. Image credit: ©everythingpossible – stock.adobe.com

European Commission grants marketing authorisation to aflibercept biosimilar EYLUXVI (ALT-L9)

Martin David Harp
October 8th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.